drugset / Trial / NCT04427917

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

NCT04427917

Phase 1 Completed 8 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants. A total of approximately 8 healthy participants will be enrolled in this study. Participants will be randomized to 2 groups to receive PF-06835919 or placebo treatment with a randomization ratio of 3:1.

Timeline

Start
2020-11-24
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06835919 Small molecule 300 mg Oral

Indications

No indication recorded.